A Phase 2 Study of PF-04449913 for the Treatment of Acute Myeloid Leukemia Patients With High Risk of Post-Allogeneic Stem Cell Transplantation Relapse

Trial Profile

A Phase 2 Study of PF-04449913 for the Treatment of Acute Myeloid Leukemia Patients With High Risk of Post-Allogeneic Stem Cell Transplantation Relapse

Recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2017

At a glance

  • Drugs Glasdegib (Primary)
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Sep 2015 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
    • 16 Jun 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
    • 10 Feb 2014 Planned number of patients changed from 17 to 28 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top